Should You Buy Gilead Stock At $110?

1. Gilead faces FDA clinical hold on HIV trials impacting stock performance. 2. Despite challenges, GILD stock rose 18% this year, outperforming S&P 500. 3. Gilead's pipeline includes 16 late-stage clinical trials, showcasing growth potential. 4. Profitability metrics indicate Gilead's strong operational performance and financial health. 5. Valuation analysis suggests Gilead is slightly undervalued compared to the S&P 500.